ReviewThe New England journal of medicine2011
Genomics and drug response.
Registry-linked trialAbstract readReview
In one paragraph
Review in The New England journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01970709 (DART Registry), which is not on this map. Cited by 259 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DART Registry: Diagnosing Adverse Drug Reactions Registry
Who cites it
259 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Efficacy and safety of ephedra-containing oral medications: a systematic review, meta-analysis, and exploratory dose-response analysis for weight reduction.Frontiers in pharmacology · 2024Pooled it
- Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.Clinical pharmacology and therapeutics · 2022Pooled it
- CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.The pharmacogenomics journal · 2020Pooled it
- US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis.JAMA network open · 2019Pooled it
- Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.Advances in therapy · 2016Pooled it
- Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials.British journal of clinical pharmacology · 2015Pooled it
- Genetic variability in thrombopoietin receptor and GATA1 influences response to eltrombopag in dengue-induced thrombocytopenia.Scientific reports · 2026Trial
- Application of Loading Dose Warfarin in Postpartum Women with Pulmonary Embolism - a Prospective, Randomized, Double-Blind Trial.Drug design, development and therapy · 2025Trial
- Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.Molecular endocrinology (Baltimore, Md.) · 2014Trial
- Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.European journal of clinical pharmacology · 2014Trial
- Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Pharmacogenomics · 2014Trial
- Genome-wide association study identifies a potent locus associated with human opioid sensitivity.Molecular psychiatry · 2014Trial
- A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome.European journal of endocrinology · 2013Trial
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Breast cancer research and treatment · 2013Trial
- Assessing the Frequency, Prescribing Patterns, and Characteristics of Patients Receiving Drugs with Pharmacogenomic (PGx) Guidelines Through an EMR: Follow-Up Analysis 5 Years Later.Pharmacy (Basel, Switzerland) · 2026Article
- Pharmacogenetics in pediatric cardiology.Frontiers in pediatrics · 2026Article
- The critical need to implement pharmacogenomics in public health services: Mexico in the global picture.Frontiers in public health · 2026Article
- Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure.PloS one · 2026Article
- Nanomotion-Based Drug Sensitivity Prediction in Ovarian and Colon Cancer Cell Lines Using Machine Learning.ACS pharmacology & translational science · 2025Article
- A review of precision medicine in developing pharmaceutical products: Perspectives and opportunities.International journal of pharmaceutics · 2025Review
199 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Liewei WangDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA.
Howard L McLeod
Richard M Weinshilboum
Funding
UNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6MPOPULATION GENETICS AND DRUG METABOLISMU01GM063340 · NIGMS · WASHINGTON UNIVERSITY · PI MCLEOD, HOWARD L · 2001 to 2009
$17.4MPharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8MINHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9MPharmacogenomics of Breast Cancer Adjuvant ChemotherapyU01HG005137 · NHGRI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2009 to 2011
$2.1MPharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemiaR01CA132780 · NCI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2008 to 2013
$1.6MPharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5MPharmacogenomics of a Cytidine Analogue, GemcitabineK22CA130828 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2008 to 2010
$492kNCI NIH HHS K22 CA130828NCI NIH HHS K22-CA130828NCI NIH HHS R01 CA132780NCI NIH HHS R01-CA132780NCI NIH HHS R01 CA138461NCI NIH HHS R01-CA138461NCRR NIH HHS UL1 RR025747NCRR NIH HHS UL1RR025747NHGRI NIH HHS U01 HG005137NHGRI NIH HHS U01-HG005137NIGMS NIH HHS R01 GM028157NIGMS NIH HHS R01-GM28157NIGMS NIH HHS U01 GM063340NIGMS NIH HHS U01-GM63340NIGMS NIH HHS U19 GM061388NIGMS NIH HHS U19-GM61388
Abstract
PubMed holds no abstract for this paper.
Indexed as
GenotypePharmacogeneticsAnti-Infective AgentsAntineoplastic AgentsAromatase InhibitorsCardiovascular AgentsClopidogrelGenome-Wide Association StudyGenomicsHumansNeoplasmsPolymorphism, GeneticTiclopidineWarfarinAnti-Infective AgentsAntineoplastic AgentsAromatase InhibitorsCardiovascular AgentsClopidogrelTiclopidineWarfarin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01970709ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.